CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
December 2020—As ongoing studies reveal the merits of emicizumab for hemophilia A patients—fewer bleeding episodes, longer duration between treatments—laboratories need to be alert to the drug’s effect on coagulation testing.
Read More »Digging into drug’s effect on aPTT-based assays
